CN118047884A - 一种木聚糖生育酚衍生物及其制备方法和应用 - Google Patents
一种木聚糖生育酚衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN118047884A CN118047884A CN202311871104.5A CN202311871104A CN118047884A CN 118047884 A CN118047884 A CN 118047884A CN 202311871104 A CN202311871104 A CN 202311871104A CN 118047884 A CN118047884 A CN 118047884A
- Authority
- CN
- China
- Prior art keywords
- xylan
- tocopherol
- tocopherol derivative
- stirring
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001221 xylan Polymers 0.000 title claims abstract description 94
- -1 Xylan tocopherol derivative Chemical class 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 230000003647 oxidation Effects 0.000 claims abstract description 5
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 5
- 229930003799 tocopherol Natural products 0.000 claims description 43
- 239000011732 tocopherol Substances 0.000 claims description 43
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 40
- 229960001295 tocopherol Drugs 0.000 claims description 40
- 235000010384 tocopherol Nutrition 0.000 claims description 40
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 37
- 238000003756 stirring Methods 0.000 claims description 29
- 150000004823 xylans Chemical group 0.000 claims description 27
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 24
- 239000000017 hydrogel Substances 0.000 claims description 24
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 230000037303 wrinkles Effects 0.000 claims description 20
- 238000009472 formulation Methods 0.000 claims description 18
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims description 16
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims description 16
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 15
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 15
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 15
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 14
- 230000003020 moisturizing effect Effects 0.000 claims description 14
- 241001480058 Quercus glauca Species 0.000 claims description 13
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 12
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 11
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 11
- 229960003639 laurocapram Drugs 0.000 claims description 11
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 11
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 11
- 229960002216 methylparaben Drugs 0.000 claims description 11
- 229960005323 phenoxyethanol Drugs 0.000 claims description 11
- 229920001285 xanthan gum Polymers 0.000 claims description 11
- 239000000230 xanthan gum Substances 0.000 claims description 11
- 229940082509 xanthan gum Drugs 0.000 claims description 11
- 235000010493 xanthan gum Nutrition 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 239000003961 penetration enhancing agent Substances 0.000 claims description 9
- 239000002562 thickening agent Substances 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 6
- 230000002000 scavenging effect Effects 0.000 claims description 6
- 230000003712 anti-aging effect Effects 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 230000003064 anti-oxidating effect Effects 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 229940127554 medical product Drugs 0.000 claims description 2
- 230000001180 sulfating effect Effects 0.000 claims description 2
- 230000002087 whitening effect Effects 0.000 claims description 2
- 229960002337 magnesium chloride Drugs 0.000 claims 2
- 208000003351 Melanosis Diseases 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 206010014970 Ephelides Diseases 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 230000009467 reduction Effects 0.000 description 12
- 238000001914 filtration Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000001815 facial effect Effects 0.000 description 9
- 125000002640 tocopherol group Chemical class 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 238000001728 nano-filtration Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000000643 oven drying Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019149 tocopherols Nutrition 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000037331 wrinkle reduction Effects 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 244000172533 Viola sororia Species 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003895 organic fertilizer Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Materials Engineering (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种木聚糖生育酚衍生物及其制备方法和应用,所述木聚糖生育酚衍生物的结构如式I所示:其中,m≥1;R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11各自独立地选自‑SO3Na或‑H,但不同时为‑H;R12为所述木聚糖生育酚衍生物具有良好的稳定性和水溶性,能够发挥抗氧化、保湿、抗衰老、祛斑和改善肤色的作用,可用于制作化妆品和药品。
Description
技术领域
本申请涉及医药、化妆品领域,具体涉及一种木聚糖生育酚衍生物及其制备方法和应用。
背景技术
在整个说明书中对现有技术的任何讨论都不应被视为承认这些现有技术是广为人知的,或构成本领域公知常识的一部分。
生育酚属于脂溶性维生素,是人体最主要的抗氧化剂之一,生育酚及其衍生物能够有效防止皮肤的氧化老化,是化妆品活性物的重要成分之一。对于简单的生育酚,其分子结构中的羟基裸露在外面,很容易被氧化,导致稳定性较差。市面上出现大量高浓度生育酚的化妆品,究其原因,本质在于生育酚易氧化失活,不得不大量添加以保持活性。生育酚外观为金黄色或淡黄色油状液体,且易被氧化变成暗红色,影响了作为化妆品的美观。
肝素类产品具有抗炎、抗过敏、改善微循环及肌肤新陈代谢的生物活性,并有软化、滋润皮肤、促进细胞增生、加速伤口愈合的作用。有利于皮肤的营养供给和代谢废物的排泄,对皮肤有良好的保健和养护作用。应用在去黑眼圈、眼袋等产品中,具有修护保湿和超强肤感,适用于乳液、膏霜、面膜、精华等产品中。类肝素与肝素具有相似的功效,通过改善皮肤微循环,降低血液粘度,促进血液微循环,达到显著的活肤美容效果。木聚糖多硫酸酯是将植物来源天然的大分子木聚糖以化学方法磺化再解聚制备的一种类肝素,作为药品用于间质性膀胱炎、关节炎等炎症治疗。
水青冈广泛分布在亚洲、欧洲与北美洲,也是温带阔叶落叶的主要构成树种之一。树木每年都要进行剪枝,保证树体枝条合理,营养充足,剪下来的废弃枝叶一般处理方式有焚烧,做成有机肥料,用作蚊香等低值化方式。
发明内容
本发明提供了一种木聚糖生育酚衍生物及其制备方法和应用。本发明所述木聚糖生育酚衍生物结构中同时含有疏水的生育酚结构和亲水的木聚糖多硫酸酯结构,两者以共价酯键结合,具有优异的稳定性和水溶性,改善了生育酚易氧化、颜色加深的问题,同时,本发明所述木聚糖生育酚衍生物还具有良好的保湿、抗氧化、抗衰老、祛斑和改善肤色的作用。此外,本发明所述的木聚糖生育酚衍生物的原料来源可以是水青冈修剪后的废枝叶,比如从水青冈修剪后的废枝叶中提取木聚糖后进行纯化、降解及磺化后与生育酚通过酯键进行偶联得到,实现了对废枝叶进行高值化回收利用。
具体地,本发明提供了下述的技术方案。
在本发明的第一方面,提供了一种木聚糖生育酚衍生物,其结构如式I所示:
其中,m≥1;R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11各自独立地选自-SO3Na或-H,但不同时为-H;
R12为
在本发明的一些实施方式中,R12在式I中的取代度为0.04-1.0;优选为0.1-0.4。
在本发明的一些实施方式中,其平均分子量为1~40kDa;优选为4kDa-10kDa。
在本发明的第二方面,提供了一种制备上述第一方面中所述的木聚糖生育酚衍生物的方法,其包括:将生育酚与戊聚糖硫酸酯共价键合形成酯键。
在本发明的一些实施方式中,所述方法包括将生育酚和戊聚糖硫酸酯在碱性环境下反应。比如,在一个实施方式中,所述方法包括:将戊聚糖硫酸酯加入至溶剂(比如二甲基甲酰胺)中,搅拌至溶清;加入生育酚、缩合剂(比如1-丙基磷酸环酐)和碱(比如三乙胺),20~30℃搅拌,反应完毕后加入至纯化水中,经后处理即得;在一些实施方式中,所述后处理程序包括过滤、洗涤、干燥即得,比如通过纳滤膜(截留分子量500Da)进行超滤、洗涤,经冻干即可得到木聚糖生育酚衍生物。
在本发明的一些实施方式中,所述戊聚糖硫酸酯的结构如式II所示:
其中,m≥1;R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11各自独立地选自-SO3Na或-H,但不同时为-H;
在本发明的一些实施方式中,所述戊聚糖硫酸酯由水青冈修剪枝叶来源的木聚糖结构经过硫酸化得到。
在一个实施方式中,所述戊聚糖硫酸酯的制备方法包括:将水青冈修剪枝叶破碎、晒干、粉碎;将粉碎后的水青冈修剪枝叶加入碱性过氧化氢溶液中,85~90℃处理;对经碱液处理过的混合物压滤,收集滤液;将滤液降至室温用浓盐酸调pH至6~7,加入至95%乙醇静置,沉降;过滤沉淀后的混合物,收集滤饼,滤饼进行重结晶;将重结晶后的产品于50-55℃真空干燥箱中干燥得到木聚糖;将木聚糖加入二甲基甲酰胺中,10℃以下加入氯磺酸,25℃~30℃反应;将反应后的混合物加入至无水乙醇中,静置;过滤收集固体;将收集的固体加入至纯化水中,搅拌溶解,10% NaOH溶液调pH 6-7;加入至95%乙醇中,静置、过滤、烘干即得。
在本发明的第三方面,提供了一种组合物,其包括上述第一方面中所述的木聚糖生育酚衍生物。
在本发明的第四方面,提供了一种制剂,其包括上述第一方面中所述的木聚糖生育酚衍生物和至少一种辅料。
如无其他说明,本发明所述木聚糖生育酚衍生物是可口服、可外用或可注射使用的,本领域技术人员可据此根据常规方法选择添加合适的辅剂,将本发明所述组合物制备成合适的剂型或使用形式。所述剂型比如注射剂、膏剂、粉针剂、搽剂、敷料、液体制剂、等等。作为化妆品时,所述组合物可以包括但不限于为化妆水、乳液、精华、凝胶、粉底、膏霜和面膜等,所述化妆品的应用范围包括但不限于面部洗护保养、身体洗护保养和头部洗护保养等等。本发明所述木聚糖生育酚衍生物可用于配置具有防晒、保湿、补充皮肤营养、抗炎、抗氧化、祛皱、抗衰老和皮肤修护等功能的化妆品。
在本发明的第五方面,提供了一种水凝胶制剂,其包括上述第一方面中所述的木聚糖生育酚衍生物、溶剂、增稠剂、粘度调节剂、促渗剂和防腐剂。
在本发明的一种实施方式中,所述水凝胶制剂的原料由木聚糖生育酚衍生物、氯化镁(粘度调节剂)、黄原胶(增稠剂)、月桂氮卓酮(促渗剂)、苯氧乙醇(防腐剂)、羟苯甲酯(防腐剂)和水组成;其中,所述木聚糖生育酚衍生物在凝胶制剂中的含量为200-400μg/mL。
在本发明的一种实施方式中,所述水凝胶制剂中还可以进一步包含透明质酸钠和氨基葡萄糖盐酸盐。
比如,在一种实施方式中,所述水凝胶制剂的原料组成为:200-400μg/mL木聚糖生育酚衍生物,0.5-1.5%透明质酸钠(200~400KDa),3.0-9.0%氨基葡萄糖盐酸盐,0.5-1.5%氯化镁,0.5-1.5%黄原胶,0.5-1.5%月桂氮卓酮,0.3-0.7%苯氧乙醇,0.05-0.15%羟苯甲酯,余量为水,上述含量均为质量百分含量。
在一个优选的实施方式中,所述水凝胶制剂的原料组成为:300μg/mL木聚糖生育酚衍生物,透明质酸钠(200~400KDa)1%,氨基葡萄糖盐酸盐6%,氯化镁1%,黄原胶1%,月桂氮卓酮1%,苯氧乙醇0.5%,羟苯甲酯0.1%,余量为水(均为质量百分含量)。
在本发明的第六方面,提供了一种制备上述第五方面中所述的水凝胶制剂的方法,其包括:
将增稠剂加入水中搅拌溶解,得到A相溶液;
将木聚糖生育酚衍生物、促渗剂、防腐剂和稳定剂加入水中搅拌至澄清,得到B相溶液;
将B相搅拌加至A相溶液中,搅拌至均一状态,降温得到水凝胶制剂;
优选地,所述水凝胶制剂中含有透明质酸钠和氨基葡萄糖盐酸盐时,所述方法包括:
将增稠剂和透明质酸加入水中搅拌溶解,得到A相溶液;
将木聚糖生育酚衍生物、氨基葡萄糖盐酸盐、促渗剂、防腐剂和稳定剂加入水中搅拌至澄清,得到B相溶液;
将B相搅拌加至A相溶液中,搅拌至均一状态,降温得到水凝胶制剂。
比如,在一个具体的实施方式中,所述水凝胶制剂的制备方法包括:
在反应器内加入所需水量的60%的水,将增稠剂和透明质酸钠加入所需水量的60%的水中,加温搅拌,充分溶解,得A相溶液;
将木聚糖生育酚衍生物、促渗剂、氨基葡萄糖盐酸盐、氯化镁及防腐剂加入剩余量的水中,搅拌至溶液澄清,得B相溶液;
将B相溶液边搅拌边缓慢加入至A相溶液,搅拌均一,降温,得到木聚糖生育酚衍生物水凝胶。
在本发明的第七方面,提供了上述第一方面中所述的木聚糖生育酚衍生物或上述第三方面中所述的组合物或上述第四方面中所述的制剂在制备具有抗氧化作用的药品或保健品中的应用。在本发明的一些实施方式中,所述抗氧化包括但不限于清除活性氧自由基(ROS)。
在本发明的第八方面,提供了上述第一方面中所述的木聚糖生育酚衍生物或上述第三方面中所述的组合物或上述第四方面中所述的制剂或上述第五方面中所述的水凝胶制剂在制备具有下述至少一种功能的化妆品、医美用产品或食品中的应用:1)抗氧化;2)保湿;3)抗衰老;4)祛斑;和5)改善肤色。
在本发明的一些实施方式中,所述抗氧化包括但不限于清除活性氧自由基。
在本发明的一些实施方式中,所述抗衰老包括但不限于减少皮肤皱纹。
在本发明的一些实施方式中,所述祛斑包括但不限于减少色斑面积。
在本发明的一些实施方式中,所述改善肤色包括但不限于美白、均匀和提亮肤色。
相较于现有技术,本发明的优势在于:
本发明提供了一种水青冈修剪枝叶来源的木聚糖生育酚衍生物及其制备方法和应用。本发明所述的水青冈修剪枝叶来源的木聚糖生育酚衍生物具有良好的补水、保湿、抗氧化、清除对机体有害的自由基、祛皱以及祛斑和改善肤色的作用,并且具备良好的水溶性和稳定性,具有良好的应用前景。
附图说明
构成本申请的一部分的说明书附图用来提供对本申请的进一步理解,本申请的示意性实施例及其说明用于解释本申请,并不构成对本申请的不当限定。以下,结合附图来详细说明本申请的实施方案,其中:
图1为实施例1制备的木聚糖生育酚衍生物的核磁谱图。
图2示出了本发明的木聚糖生育酚衍生物和生育酚水溶性试验对比结果图。
图3示出了本发明所述实施例4皮肤水分增长率值的变化图。
图4示出了本发明所述实施例4皮肤皱纹减少量对比图(%)。
具体实施方式
下面结合具体实施例,进一步阐述本申请。应理解,这些实施例仅用于说明本申请而不用于限制本申请的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件或按照制造厂商所建议的条件。
除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。本申请所使用的试剂或原料均可通过常规途径购买获得,如无特殊说明,本申请所使用的试剂或原料均按照本领域常规方式使用或者按照产品说明书使用。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本申请方法中。文中所述的较佳实施方法与材料仅作示范之用。
本发明提供了一种木聚糖生育酚衍生物,其结构如式I所示:
其中,m≥1;R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11各自独立地选自-SO3Na或-H,但不同时为-H;
R12为(即生育酚基团)。
在一些优选地方式中,R12在式I中的取代度为0.04-1.0;优选为0.1-0.4;式I的平均分子量为1~40kDa;优选为4kDa-10kDa。该范围内的木聚糖生育酚衍生物具有相似且稳定的性质。
本发明还提供了一种制备式I所示的木聚糖生育酚衍生物的方法,其包括:将生育酚与戊聚糖硫酸酯共价键合形成酯键;其反应路线如下所示:
具体地,本发明所述衍生物的制备及性质将以下述实施例进行示意说明,应当理解的,实施例的设置只为示意,难以穷举,本领域技术人员根据本发明所述能够容易的制备得到具有本发明所述结构的衍生物或者与本发明结构相似的其他衍生物,并通过核磁谱图进行结构验证。
实施例1木聚糖生育酚衍生物(式I)的制备
将水青冈修剪枝叶破碎、晒干、进一步粉碎后,取4kg加入20L碱性过氧化氢溶液(3%的30%过氧化氢溶液,10% NaOH),85~90℃处理16小时。压滤,收集滤液。滤液降至室温用浓盐酸调pH至6~7,加入至80L 95%乙醇静置,沉降,过滤,滤饼经过重结晶后于50-55℃真空干燥箱中干燥得到木聚糖196g。将木聚糖加入10L二甲基甲酰胺中,10℃以下加入300ml氯磺酸,25℃~30℃反应5小时,加入至40L无水乙醇中,静置。过滤搜集固体后,加入至2L纯化水中,搅拌溶解,10% NaOH溶液调pH 6-7。加入至8L 95%乙醇中,静置、过滤、烘干得木聚糖多硫酸酯,也称为戊聚糖硫酸酯190g。
将190.0g戊聚糖硫酸酯加入至2L二甲基甲酰胺中,搅拌至溶清。加入430.4g生育酚、381.6g 1-丙基磷酸环酐及121.2g三乙胺,20~30℃搅拌16小时,反应完毕后加入至20L纯化水中。通过纳滤膜(截留分子量500Da)进行超滤、洗涤,经冻干得到木聚糖生育酚衍生物,平均分子量为6kDa,生育酚取代度为0.12。其核磁谱图如图1所示。
实施例2木聚糖生育酚衍生物(式I)的制备
将水青冈修剪枝叶破碎、晒干、进一步粉碎后,取4kg加入16L碱性过氧化氢溶液(2%的30%过氧化氢溶液,10% NaOH),85~90℃处理16小时。压滤,收集滤液。滤液降至室温用浓盐酸调pH至6~7,加入至64L 95%乙醇静置,沉降,过滤,滤饼经过重结晶后于50-55℃真空干燥箱中干燥得到木聚糖209g。将木聚糖加入10L二甲基甲酰胺中,10℃以下加入300ml氯磺酸,25℃~30℃反应5小时,加入至40L无水乙醇中,静置。过滤搜集固体后,加入至2L纯化水中,搅拌溶解,10% NaOH溶液调pH 6-7。加入至8L 95%乙醇中,静置、过滤、烘干得木聚糖多硫酸酯,也称为戊聚糖硫酸酯201g。
将200.0g戊聚糖硫酸酯加入至2L二甲基甲酰胺中,搅拌至溶清。加入430.4g生育酚、381.6g 1-丙基磷酸环酐及121.2g三乙胺,20~30℃搅拌16小时,反应完毕后加入至20L纯化水中。通过纳滤膜(截留分子量500Da)进行超滤、洗涤,经冻干得到木聚糖生育酚衍生物,平均分子量为9kDa,生育酚取代度为0.11。
本发明所述的木聚糖生育酚衍生物的平均分子量为1~40kDa,优选为4kDa-10kDa,生育酚在木聚糖生育酚衍生物中的取代度为0.04-1.0,优选为0.1-0.4。该范围内的木聚糖生育酚衍生物具有相似且稳定的性质。改变上述实施例1和实施例2所示意的制备过程中的参数能够影响产品的分子量和取代度,通过调整上述实验过程获取所需分子量和取代度的产品对于本领域技术人员而言是容易实现的,本发明对此不再赘述。
下面进一步说明本发明的木聚糖生育酚衍生物的性能。
实施例3稳定性、水溶性试验
1、稳定性试验
对实施例1中制备得到的式I化合物进行光、热的稳定性实验,并以生育酚进行比较,结果均表现出显著优于生育酚的稳定性。其中,试验方法及结果如下所示:
强光稳定性试验:将生育酚及实施例1中制备得到的式I化合物同时置于试验箱中,在照度为3000lx的条件下放置4天。取样检测(紫外-可见分光光度法)生育酚含量的下降程度以及实施例1中制备得到的式I化合物中生育酚含量的下降程度,结果如表1所示。
表1
热稳定性试验:将生育酚及实施例1中制备得到的式I化合物同时置于避光真空干燥箱中,40~45℃放置8天。取样检测(紫外-可见分光光度法)生育酚含量的下降程度以及实施例1中制备得到的式I化合物中生育酚含量的下降程度,结果如表2所示。将生育酚及实施例1中制备得到的式I化合物同时置于避光真空干燥箱中,70~75℃放置4天。取样检测(紫外-可见分光光度法)生育酚含量的下降程度以及实施例1中制备得到的式I化合物中生育酚含量的下降程度,结果如表3所示。
表2
表3
通过以上稳定性试验对比,本发明的木聚糖生育酚衍生物具有较高的光、热环境稳定性,且均远优于生育酚。
2、水溶性试验
溶解度的评价:将实施例1中制备得到的式I化合物以4mg/ml的浓度分别溶解于纯化水中。生育酚用作对照。可以确认生育酚在相同浓度下几乎不溶于水,因此处于不透明状态,而本发明的式I化合物均完全溶于水(参见图2),表现出显著改善的水溶性。
实施例4
本实验例检测受试样品的抗炎、抗衰老及祛皱效果。
实验分组及受试样品:
各实验组凝胶质量配比如下:
实验组1:实施例1中制得的木聚糖生育酚衍生物(添加量为300μg/mL),透明质酸钠(200~400KDa)1%,氨基葡萄糖盐酸盐6%,氯化镁1%,黄原胶1%,月桂氮卓酮1%,苯氧乙醇0.5%,羟苯甲酯0.1%,余量为水。
实验组2:生育酚(添加量为300μg/mL),透明质酸钠(200~400KDa)1%,氨基葡萄糖盐酸盐6%,氯化镁1%,黄原胶1%,月桂氮卓酮1%,苯氧乙醇0.5%,羟苯甲酯0.1%,余量为水。
实验组3:木聚糖多硫酸酯(添加量为300μg/mL),透明质酸钠(200~400KDa)1%,氨基葡萄糖盐酸盐6%,氯化镁1%,黄原胶1%,月桂氮卓酮1%,苯氧乙醇0.5%,羟苯甲酯0.1%,余量为水。
实验组4:木聚糖多硫酸酯与生育酚的简单混合物(添加量为300μg/mL),透明质酸钠(200~400KDa)1%,氨基葡萄糖盐酸盐6%,氯化镁1%,黄原胶1%,月桂氮卓酮1%,苯氧乙醇0.5%,羟苯甲酯0.1%,余量为水。
空白实验组5:透明质酸钠(200~400KDa)1%,氨基葡萄糖盐酸盐6%,氯化镁1%,黄原胶1%,月桂氮卓酮1%,苯氧乙醇0.5%,羟苯甲酯0.1%,余量为水。
制备所述凝胶实验组的方法,可按如下步骤实施:
(1)按上述比例称取各组分,在反应器内加入所需水量的60%的水,将增稠剂(黄原胶)和透明质酸钠加入反应器,以150r/min转速,50℃搅拌,充分溶解,得A相溶液;
(2)在另一反应器内,加入所需水量40%的水,分别加入实施例1中制得的木聚糖生育酚衍生物、木聚糖多硫酸酯生育酚、木聚糖多硫酸酯、木聚糖多硫酸酯与生育酚的简单混合物,促渗剂(月桂氮卓酮)、氨基葡萄糖盐酸盐、氯化镁及防腐剂(苯氧乙醇和羟苯甲酯),以150r/min机械搅拌至溶液澄清,得B相溶液;
(3)将B相溶液边搅拌边缓慢加入至A相溶液,以150r/min转速搅拌均一,降温至20℃,得到木聚糖生育酚衍生物复合水凝胶。
1.保湿效果:
1.1受试者:选取30名志愿者,年龄在25~55周岁,对其面部皮肤进行实验。
1.2受试样品:将上述实验组1-5(其中实验组5为空白组)的样品作为受试物;
1.3试验前:受试者需要统一用清水清洗面部,洗净后在受试者面部下巴处,做好测量标记。受试者在恒定环境中静坐30min。
1.4试验中:将实验组1-5的水凝胶各0.5g均匀涂抹于志愿者面部下巴处皮肤。实验前,使用Corneometer CM 825水分测试仪进行受试部位空白值的测量,得到初始值V0,然后计时开始涂抹受试品。面部水分增长率%=(Vt-V0)/V0
表1皮肤水分增长率值的变化表
由表1可以看出,随着时间的延长,皮肤表面水分增长率逐渐降低,只涂抹具有保湿效果的透明质酸的空白组水分散失最快。涂抹了木聚糖生育酚衍生物复合水凝胶的皮肤保湿效果最好,水分增长率下降的最慢,四小时后依旧有较强的补水保湿作用,在整个使用周期内均表现出最好的效果。而仅涂抹含有生育酚和木聚糖多硫酸酯及两者的简单混合物的凝胶补水效果明显低于实验组1,这表明本发明的优异补水效果并不是生育酚和木聚糖多硫酸酯的简单混合的结果,而是本发明提供的衍生物的特殊结构导致,本发明的木聚糖生育酚衍生物通过化学改性发挥了木聚糖多硫酸酯和生育酚的双重补水协同效果,且效果优于透明质酸,且共价键偶联的方式生成的柔性结构更易于皮肤的吸收并进行深层补水,从而延长了产品的半衰期,达到长效保湿的作用。
2.祛皱功效评价
1.1受试者:选取30名志愿者,年龄在25~55周岁,对其面部皮肤进行实验。
1.2受试样品:将上述实验组1-5(其中实验组5为空白组)的样品作为受试物;
1.3试验前:先通过Visioline VL 650皱纹测试仪测定试验前的受试者脸部皮肤皱纹面积S0:皮肤皱纹的硅胶复制膜片的变化,经软件分析得到脸部皮肤皱纹面积的变化。
1.4试验中:志愿者按照使用方法使用受试样品,分别于每天下午2点(测量环境温度为20℃,相对湿度为50%),通过Visioline VL 650皱纹测试仪测定脸部皮肤皱纹面积St:皮肤皱纹的硅胶复制膜片的变化,经软件分析得到脸部皮肤皱纹面积的变化。
最后,计算皮肤皱纹面积减少量(%)=(试验前皮肤皱纹面积-试验后平均皮肤皱纹面积)/试验前皮肤皱纹面积×100%。
表2皮肤皱纹减少量(%)
由表2可以看出,实验组5(空白组)的皮肤皱纹面积几乎没有变化,证明人体脸部皮肤皱纹在不施用去皱产品的时候,其自身皱纹形成后不会自行消失;含木聚糖生育酚衍生物的实验组1凝胶祛皱效果最显著,其效果随时间持续增强,显著高于生育酚和木聚糖多硫酸酯及两者的简单混合物凝胶。这说明本发明的木聚糖生育酚衍生物相较于其他组的活性成分具有明显延长的半衰期,能够更好的起到加速皮肤更新,增强皮肤物理屏障的功能,达到更好的祛皱效果。
3.抗氧化、清除自由基(ROS)效果评价
原理:本发明采用NBT(硝基蓝四唑)光化还原法测定样品的抗氧化活性。NBT被O2 ·-还原为蓝紫色物质,这种物质对530~580nm均呈现最大吸收,当抗氧化样品存在时,NBT还原反应可能受到抑制。首先通过黄嘌呤-黄嘌呤氧化酶系统酶促产生超氧化物阴离子,随后分光光度法监测在560nm处NBT的还原。
测定方法:①首先配置50μM,2ml的黄嘌呤于试管中,加入适当量的黄嘌呤氧化酶,以便产生0.024△A min-1,相当于1.1μMmin-1的O2 ·-产率。
②准确称取0.0123g NBT,0.381g甲硫氨酸(Met),量取200μl 100mmol/L的EDTA,再加入0.05mol/LpH7.8的磷酸缓冲液至200ml。
取反应液②3ml加入反应液①中,再向试管中加入待测液1ml。在37℃的水浴条件下,2×40W日光灯照射20min后结束反应,并将试管置于黑暗条件下。使用具有1cm的光路、恒温调节并装备有磁力搅拌的比色皿在25±0.2℃下进行测量。比较其I50值(即产生NBT还原抑制50%的浓度)。
表3清除活性氧自由基(ROS)效果考察
样品 | I50值/μM |
实验组1 | 0.2(±0.03) |
实验组2 | 1.5(±0.05) |
实验组3 | 1.6(±0.04) |
实验组4 | 0.7(±0.07) |
实验组5 | 2.4(±0.02) |
获得I50值的产物的量越小,其抗氧化活性越大。从表3数据分析,实验组1的I50值仅有0.2μM,表明其在低浓度下就具有很强的自由基抑制效果,显示出很高的活性,且显著优于其他实验组的效果,特别是也明显优于木聚糖多硫酸酯与生育酚的简单混合物(实验组4),这充分证明了本发明制得的木聚糖生育酚衍生物的抗氧化效果并不是木聚糖多硫酸酯与生育酚简单混合产生的,而是结构使然。
4.祛斑效果考察
根据研究,亚洲人和深色皮肤的人更容易出现色素沉着。本发明选取30名年龄在25-55岁之间脸部出现褐斑且肤质敏感的中国女性志愿者进行研究,评估木聚糖生育酚衍生物的脱色效果。通过分光光度法测量从0到255(灰度等级:0=黑色,255=白色,数值增加表示脱色效果增强)的灰色水平来评估着色,并通过Dunnett-t检验进行方差分析和计算p值。每天分别在志愿者的脸部指定部位皮肤上涂抹实验组1的凝胶两次,两次涂抹间隔时间超过1小时,连续涂抹8周,并用Siascope采集皮肤图像,识别如黑素的发色团。指定点及其正常相邻皮肤的灰度(颜色)和表面显示M89PF降低了黑斑的面积和颜色(见表4)。
表4木聚糖生育酚衍生物凝胶对肤色及褐斑表面积的影响
表4结果表明木聚糖生育酚衍生物对改善肤色(变亮),减少褐斑面积,以及提升周围皮肤颜色等级有显著效果,且这些效果随着时间的推移而增强。
以上所述仅为本申请的优选实施例而已,并不用于限制本申请,尽管参照前述实施例对本申请进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本申请的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本申请的保护范围之内。
Claims (10)
1.一种木聚糖生育酚衍生物,其结构如式I所示:
其中,m≥1;
R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11各自独立地选自-SO3Na或-H,但不同时为-H;
R12为
2.根据权利要求1所述的木聚糖生育酚衍生物,其特征在于,R12在式I中的取代度为0.04-1.0;优选为0.1-0.4。
3.根据权利要求1所述的木聚糖生育酚衍生物,其特征在于,其平均分子量为1~40kDa;优选为4kDa-10kDa。
4.一种制备权利要求1至3中任一项所述的木聚糖生育酚衍生物的方法,其包括:将生育酚与戊聚糖硫酸酯在碱性环境下反应共价键合形成酯键;
其中,所述戊聚糖硫酸酯的结构如式II所示:
m≥1;R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11各自独立地选自-SO3Na或-H,但不同时为-H;
优选地,所述戊聚糖硫酸酯由水青冈修剪枝叶来源的木聚糖结构经过硫酸化得到。
5.一种组合物,其包括权利要求1至3中任一项所述的木聚糖生育酚衍生物。
6.一种制剂,其包括权利要求1至3中任一项所述的木聚糖生育酚衍生物和至少一种辅料。
7.一种水凝胶制剂,其包括权利要求1至3中任一项所述的木聚糖生育酚衍生物、溶剂、增稠剂、稳定剂、促渗剂、粘度调节剂和防腐剂;
优选地,所述水凝胶制剂的原料由木聚糖生育酚衍生物、氯化镁、黄原胶、月桂氮卓酮、苯氧乙醇、羟苯甲酯和水组成;
优选地,所述木聚糖生育酚衍生物在凝胶制剂中的含量为200-400μg/mL;
优选地,所述水凝胶制剂中还可以包含透明质酸钠和氨基葡萄糖盐酸盐;
优选地,所述透明质酸钠的分子量为200~400KDa;
优选地,所述水凝胶制剂的原料组成为:200-400μg/mL木聚糖生育酚衍生物,0.5-1.5wt%透明质酸钠,3.0-9.0wt%氨基葡萄糖盐酸盐,0.5-1.5wt%氯化镁,0.5-1.5wt%黄原胶,0.5-1.5wt%月桂氮卓酮,0.3-0.7wt%苯氧乙醇,0.05-0.15wt%羟苯甲酯,余量为水。
8.一种制备权利要求7中所述的水凝胶制剂的方法,其包括:
将增稠剂加入水中搅拌溶解,得到A相溶液;
将木聚糖生育酚衍生物、促渗剂、防腐剂、粘度调节剂和稳定剂加入水中搅拌至澄清,得到B相溶液;
将B相搅拌加至A相溶液中,搅拌至均一状态,降温得到水凝胶制剂;
优选地,所述水凝胶制剂中含有透明质酸钠和氨基葡萄糖盐酸盐时,所述方法包括:
将增稠剂和透明质酸加入水中搅拌溶解,得到A相溶液;
将木聚糖生育酚衍生物、氨基葡萄糖盐酸盐、促渗剂、防腐剂、粘度调节剂和稳定剂加入水中搅拌至澄清,得到B相溶液;
将B相搅拌加至A相溶液中,搅拌至均一状态,降温得到水凝胶制剂。
9.权利要求1至3中任一项所述的木聚糖生育酚衍生物或权利要求5中所述的组合物或权利要求6中所述的制剂在制备具有抗氧化作用的药品或保健品中的应用;
优选地,所述抗氧化包括清除活性氧自由基。
10.权利要求1至3中所述的木聚糖生育酚衍生物或权利要求5中所述的组合物或权利要求6中所述的制剂或权利要求7中所述的水凝胶制剂在制备具有下述1)至5)中至少一种功能的化妆品、医美用产品或食品中的应用:1)抗氧化;2)保湿;3)抗衰老;4)祛斑;和5)改善肤色;
优选地,所述抗氧化包括清除活性氧自由基;
优选地,所述抗衰老包括减少皮肤皱纹;
优选地,所述祛斑包括减少色斑面积;
优选地,所述改善肤色包括美白、均匀和提亮肤色。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311871104.5A CN118047884A (zh) | 2023-12-29 | 2023-12-29 | 一种木聚糖生育酚衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311871104.5A CN118047884A (zh) | 2023-12-29 | 2023-12-29 | 一种木聚糖生育酚衍生物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118047884A true CN118047884A (zh) | 2024-05-17 |
Family
ID=91043928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311871104.5A Pending CN118047884A (zh) | 2023-12-29 | 2023-12-29 | 一种木聚糖生育酚衍生物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118047884A (zh) |
-
2023
- 2023-12-29 CN CN202311871104.5A patent/CN118047884A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100825450B1 (ko) | 연교추출물을 함유하는 피부 주름개선용 화장료 조성물 | |
CN110236981B (zh) | 一种美白植物多糖组合物及其应用 | |
KR101669528B1 (ko) | 헤파란 술페이트의 정제 방법 및 미용학적 및 피부학적 제제에서 그의 용도 | |
CN116003577B (zh) | 一种用于皮肤舒缓修复的重组胶原蛋白及其应用 | |
JP4831849B2 (ja) | 活性酸素消去剤およびその用途 | |
JP3193441B2 (ja) | 美白化粧料 | |
KR20120021407A (ko) | 녹차 가수분해물을 유효성분으로 포함하는 항산화, 피부미백, 항노화용 조성물 | |
CN111529474A (zh) | 保湿美白抗氧化修护的多效组合物及其制备方法与应用 | |
KR101142541B1 (ko) | 효소처리를 이용한 혼합생약재 추출물을 함유하는 피부 주름개선용 화장료 조성물 및 그 추출방법 | |
KR20030064059A (ko) | 목단피추출물과 자귀나무추출물을 함유하는 노화방지화장료 조성물 | |
KR102606356B1 (ko) | 피부주름 개선용 화장료 조성물 | |
CN113876610A (zh) | 一种能够增强细胞能量并提高皮肤抵抗力的组合物及其制备方法与应用 | |
CN116284495B (zh) | 全反式维甲酸低分子透明质酸酯衍生物及其制备方法和应用 | |
CN111603404B (zh) | 一种含细胞提取液的护肤精华液及其制备方法 | |
KR20110109568A (ko) | 맥주 효모를 이용한 미백 화장료 조성물 | |
CN111568781A (zh) | 一种护肤凝胶及其制备方法 | |
KR102381645B1 (ko) | 복령발효추출물을 포함하는 화장료 조성물 | |
CN118047884A (zh) | 一种木聚糖生育酚衍生物及其制备方法和应用 | |
KR100371504B1 (ko) | 분말 상의 포도 발효액 추출물을 함유하고 미백 및 주름방지 효과를 갖는 화장료 조성물 | |
CN113876626B (zh) | 一种对蓝光诱导皮肤细胞损伤具有保护作用的组合物及其在化妆品中的应用 | |
WO2012169818A2 (ko) | 군소 추출물을 함유하는 피부 보습 및 주름 개선용 화장용 조성물 | |
KR102310366B1 (ko) | 시아니딘글루코사이드 및 낫토검을 유효성분으로 함유하는 항노화용 피부 외용제 조성물 | |
KR100680845B1 (ko) | 신이화로부터 다당체인 마그놀란을 추출하는 방법 및 이를 이용한 화장품 조성물 | |
CN111449997A (zh) | 一种使用绿藻提取物作为主要活性成分的化妆品 | |
KR20100090533A (ko) | 보령산 머드 추출물의 추출방법 및 그 추출물을 함유하는 미백기능성 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |